Drug Trial Radar · NCT05352919
A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)
Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
864
Planned (sponsor's estimate)
Start
Jun 10, 2022
Primary completion
May 3, 2032
Study completion May 3, 2032
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with systemic lupus erythematosus (SLE). The study will focus on adults who have active disease and are already taking standard of care medications. These may include antimalarials, steroids, and immunosuppressants. This is an extension study of 230LE303 and 230LE304 (TOPAZ-1 and TOPAZ-2). It will include participants who completed the treatment periods of either one of those parent studies. The main goal of the study is to learn more about the long-term safety of litifilimab in adults. The main question researchers want to answer is: \- How many participants have adverse events and serious adverse events during the study? Adverse events are health problems that may or may not be caused by the study drug. Researchers will also learn about: * The effect of litifilimab on controlling symptoms of SLE and lowering its activity. * How participants' immune systems respond to litifilimab. * The effect of litifilimab on the quality of life of participants. The study will be done as follows: * This study begins when the participant has finished 1 of the parent studies (either 230LE303 or 230LE304). * Participants who were getting either a high or low dose of litifilimab in either parent study will continue getting the same doses. * Participants who were getting the placebo in the parent studies will be randomized to get either a high or low dose of litifilimab. * Neither the researchers nor the participants will know which doses of litifilimab the participants are getting. * All participants will get litifilimab as injections under the skin once every 4 weeks. The treatment period will last up to 260 weeks. Participants may continue to take their standard of care medications. * There will be a follow-up safety period that lasts up to 24 weeks. * In total, participants will have up to 73 study visits. At these visits, the study doctor will do tests to check the participants' overall health, including the status of their SLE symptoms. They will also measure the participants' height, weight, and vital signs and collect blood and urine samples. Participants will also complete questionnaires or answer questions about how they are feeling and about their daily lives. * Each participant will be in the study for up to 284 weeks. Optional Substudy: * Some participants may be invited to join an optional "substudy" after being in the main study for at least 4 months. * This substudy will test a new injector device for delivering litifilimab. The injector device is an automatic device that delivers the full dose in 1 injection without needing to push a plunger. * Researchers will learn more about the safety of the injector device and how the body reacts to it. This will be compared to the current prefilled syringe method. * The substudy will last up to 3 months and will include about 120 participants.
Conditions
- Systemic Lupus Erythematosus (SLE)
Interventions
LitifilimabDrug
Administered as specified in the treatment arm.
Litifilimab-matching placeboDrug
Administered as specified in the treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to Week 284
- Number of Participants with Serious Adverse Events (SAEs)Time frame: Up to Week 284
Locations
214 sites in 28 countries. Site status is shown where the registry gives one.
Arizona Arthritis & Rheumatology Associates, P.C.
Phoenix, Arizona
Wallace Rheumatic Study Center
Beverly Hills, California
Care Access Research - Huntington Beach
Huntington Beach, California
Providence Facey Medical Foundation
Mission Hills, California
Inland Rheumatology Clinical Trials, Inc.
Upland, California
University of Colorado Denver
Aurora, Colorado
Georgetown University Hospital-Medstar
Washington D.C., District of Columbia
Arthritis & Rheumatic Disease Specialties
Aventura, Florida
Highlands Research Institute
Avon Park, Florida
Clinical Research of West Florida - Corporate
Clearwater, Florida
GNP Research at Mark Jaffe, MD
Cooper City, Florida
Omega Research Consultants
DeBary, Florida
Life Clinical Trials
Margate, Florida
HMD Research, LLC
Orlando, Florida
Clinical Research of West Florida, Inc.
Tampa, Florida
AdventHealth Medical Group
Tampa, Florida
Arthritis Center of North Georgia
Gainesville, Georgia
University of Massachusetts Chan Medical School
Worcester, Massachusetts
AA MRC LLC Ahmed Arif Medical Research Center
Flint, Michigan
Precision Comprehensive Clinical Research Solutions
Rochester Hills, Michigan
Saint Louis Rheumatology
St Louis, Missouri
NYU Langone Brooklyn
Brooklyn, New York
DJL Clinical Research, PLLC
Charlotte, North Carolina
Onyx Clinical Research, LLC
Salisbury, North Carolina
University of Cincinnati
Cincinnati, Ohio
Paramount Medical Research & Consulting, LLC
Middleburg Heights, Ohio
West Tennessee Research Institute
Jackson, Tennessee
Ramesh C Gupta, MD
Memphis, Tennessee
Arthritis & Rheumatology Research Institute
Allen, Texas
Tekton Research - PARENT
Austin, Texas
Accurate Clinical Research
Baytown, Texas
Precision Comprehensive Clinical Research Solution
Colleyville, Texas
Prolato Clinical Research Center
Houston, Texas
Accurate Clinical Research, Inc.
Humble, Texas
R and H Clinical Research
Katy, Texas
Sun Research Institute, LLC
San Antonio, Texas
Advanced Rheumatology of Houston
The Woodlands, Texas
Swedish Medical Center
Seattle, Washington
Hospital Italiano de La Plata
Buenos Aires, Argentina
Instituto de Investigaciones Clinicas Quilmes
Buenos Aires, Argentina
Showing 40 of 214 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.